Valuation: Adocia

Market Cap 8.15Cr 9.33Cr 7.48Cr 6.98Cr 13Cr 888.06Cr 13Cr 90Cr 35Cr 435.59Cr 35Cr 34Cr 1.5TCr P/E 2026 *
16.8x
P/E 2027 * -10.3x
Enterprise Value 3.27Cr 3.75Cr 3.01Cr 2.8Cr 5.32Cr 356.77Cr 5.41Cr 36Cr 14Cr 174.99Cr 14Cr 14Cr 602.97Cr EV / Sales 2026 *
0.85x
EV / Sales 2027 * -0.68x
Free-Float
89.7%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 80 24/02/2012
Director/Board Member 58 18/06/2013
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 9.28Cr
+3.98%+5.55%+76.40%+136.18% 5.62TCr
-3.12%+5.11%+71.57%+94.67% 5.54TCr
+3.05%+7.53%-10.61%-10.24% 2.38TCr
+1.99%+4.68%+11.31%+427.01% 2.32TCr
+3.64%+10.54%+39.81%-4.50% 1.81TCr
+4.11%+8.89%+44.60%-27.73% 1.68TCr
+2.57%+20.26%+181.98%+355.99% 1.59TCr
+1.82%+3.19%+24.00%+187.14% 1.36TCr
+7.20%+10.70%+42.91% - 1.3TCr
Average +2.52%+7.25%+53.55%+144.81% 2.62TCr
Weighted average by Cap. +1.96%+6.09%+57.27%+135.43%

Financials

2026 *2027 *
Net sales 3.84Cr 4.39Cr 3.52Cr 3.29Cr 6.23Cr 418.22Cr 6.34Cr 42Cr 16Cr 205.14Cr 16Cr 16Cr 706.84Cr 1.48Cr 1.69Cr 1.35Cr 1.26Cr 2.39Cr 160.71Cr 2.44Cr 16Cr 6.32Cr 79Cr 6.34Cr 6.2Cr 271.62Cr
Net income 39.76L 45.5L 36.51L 34.05L 64.55L 43Cr 65.64L 4.4Cr 1.7Cr 21Cr 1.71Cr 1.67Cr 73Cr -80.08L -91.65L -73.54L -68.58L -1.3Cr -87Cr -1.32Cr -8.85Cr -3.43Cr -43Cr -3.44Cr -3.37Cr -147.46Cr
Net Debt -4.88Cr -5.58Cr -4.48Cr -4.18Cr -7.92Cr -531.3Cr -8.05Cr -54Cr -21Cr -260.6Cr -21Cr -20Cr -897.94Cr -9.15Cr -10Cr -8.4Cr -7.83Cr -15Cr -996.58Cr -15Cr -101.13Cr -39Cr -488.81Cr -39Cr -38Cr -1.68TCr
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-